Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03533023
Other study ID # 172083
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 8, 2018
Est. completion date March 4, 2021

Study information

Verified date August 2021
Source University of California, San Diego
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is the first study of its kind to assess and test an intervention to improve biological rhythms and general health of shift workers, specifically first responders with San Diego Fire and Rescue. In a randomized control trial, investigators intend to measure the health impact of Time Restricted Eating in emergency responders who work a 24-hour shift schedule.


Description:

Participants will be randomly assigned to a control group of behavioral nutrition counseling (standard of care) or the intervention group of standard of care with the addition of adopting a 10 hour eating window for one year (TRE). For the first 3 months of intervention, participants will be monitored closely by the research team. For the following 9 months, participants will be in a self-monitored intervention period. Investigators will evaluate the impact of TRE on blood glucose levels, biomarkers, sleep/mood, and weight loss. These assessments will be made at baseline, at the end of the 12-week monitored intervention period, and every 3 months (months 6, 9, and 12) during the self-monitored intervention period for one year. Food/drink intake, activity, and sleep will be monitored with the smartphone myCircadianClock application ("mCC app") throughout the study. A continuous glucose monitor, a wrist-worn actigraphy device, and questionnaires will also be used during the study.


Recruitment information / eligibility

Status Completed
Enrollment 153
Est. completion date March 4, 2021
Est. primary completion date March 4, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 65 Years
Eligibility As per recommendations from the fire department, fire department unions, and funding agencies, we did not require compromised health measures (e.g. hyperglycemia, hypertension, etc.) as inclusion criteria for they would be discriminatory against some firefighters. Inclusion Criteria: - Firefighter or work a 24-hr shift schedule with San Diego Fire and Rescue - Age: 21-65 years - Own a smartphone (Apple or Android Operating System) - If participants are on cardiovascular medications (HMG-CoA reductase inhibitors (statins), other lipid modifying drugs (including over the counter drugs such as red yeast rice and fish oil), anti-hypertensive, anti-diabetes drugs), no dose adjustments will be allowed during the study period Exclusion Criteria: - Insulin-dependent diabetes mellitus - Presence of acute chronic inflammatory or autoimmune disease (defined by acute symptoms or C-reactive protein >10 mg/L), malabsorption syndromes, liver disease, or kidney disease (stage 3 or greater) - Uncontrolled thyroid disease - Intake of drugs likely to interfere with study endpoints, including corticosteroids, anabolic steroids, anti-psychotics, antiretroviral drugs, and immunosuppressive drugs (within 3 months of starting the study) - Presence or recent history of anemia (hematocrit <33% within 3 months of starting the study) - History of bariatric surgery - Pregnant or breast-feeding women - Current or recent (within 12 months of starting the study) pregnancy or breastfeeding, or intention of becoming pregnant in the next 6 months - Any cancer other than non-melanoma skin cancer in the last 3 years - On a special or prescribed diet for other reasons (e.g. Celiac disease) - Depression determined by the Beck Depression Inventory (BDI) - Planned international travel during study period - Insufficient logging on the mCC app (does not log at least 2 entries a day for 10 of 14 days) during baseline will exclude from being randomized into the intervention period

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Time Restricted Eating + Standard of Care
Participants in this arm will adhere to a daily, consistent 10-hr eating window for the course of the study as well as receive nutritional counseling from the study dietician.
Standard of Care
Participants in this arm will receive nutritional counseling from the study dietician, but will not be required to adopt a 10-hr eating window.

Locations

Country Name City State
United States University of California, San Diego La Jolla California

Sponsors (2)

Lead Sponsor Collaborator
University of California, San Diego Salk Institute for Biological Studies

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Body mass index (kg/m^2) Calculated from body weight (kg) and height (m). Note: Significant changes expected in participants who had elevated BMI at baseline. No significant changes expected in those whose BMI was not elevated at baseline. primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
Other Waist and hip circumference (cm) Measured with standardized body tape measure. Note: Significant changes expected in participants who had increased waist and hip circumference at baseline. No significant changes expected in those without increased waist and hip circumference at baseline. primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
Other Hip (cm)/waist (cm) ratio Measured using tape measure. Note: Significant changes expected in participants who had an increased hip/waist ratio at baseline. No significant changes expected in those without increases at baseline primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
Other Body composition including but not limited to fat percentage (%), fat mass (kg), and lean mass (kg) Measured by Tanita Digital Scale. Note: Significant changes expected in participants who had elevations levels at baseline. No significant changes expected in those without elevations at baseline. primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
Other Questionnaires (quality of life, sleep, and health) Measured by SF-36, PSQI, and ESS. Note: Significant changes expected in participants who had decreased self-reporting of the above-mentioned questionnaires at baseline. No significant changes expected in those without decreases at baseline. primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
Primary Evaluate the impact of TRE on glucose homeostasis at end of intervention compared to baseline Measured by an ambulatory continuous glucose monitoring device and blood work throughout the study.
Note: Significant changes expected in participants who had elevated glucose homeostasis at baseline. No significant changes expected in those within normal ranges at baseline. Primary endpoint analysis will be done by comparing baseline and 12-week intervention.
primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
Primary Assess the feasibility and adherence of TRE Measured by percentage of days logged that participants ate within their 10-hour window and by end of study responses.
Note: Significant changes expected in participants in the TRE arm of the study on and off shift. No significant changes expected in the standard of care arm of the study. Primary endpoint analysis will be done by comparing baseline and 12-week intervention.
primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
Secondary Assess changes in metabolic biomarkers in response to TRE at end of intervention compared to baseline Measured with blood biochemistry.Measured with blood biochemistry under TRE, including, but not limited to: fasting glucose, HbA1c, cholesterol, and triglycerides.
Note: Significant changes expected in participants who had abnormal levels at baseline (e.g. elevated LDL cholesterol, low HDL cholesterol, elevated triglycerides). No significant changes expected in those were within normal ranges at baseline.
Timeframe: primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
Secondary Systolic blood pressure (mmHg) in response to TRE at end of intervention compared to baseline Measured at baseline and during TRE intervention. Note: Significant changes expected in participants who had elevated systolic blood pressure at baseline. No significant changes expected in those without elevated systolic blood pressure at baseline. Timeframe: primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
Secondary Diastolic blood pressure (mmHg) in response to TRE at end of intervention compared to baseline Measured at baseline and during TRE intervention. Note: Significant changes expected in participants who had elevated diastolic blood pressure at baseline. No significant changes expected in those without elevated diastolic blood pressure at baseline. primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
Secondary Body weight (kg) Measured on a digital scale. Note: Significant changes expected in participants who had elevated weight at baseline. No significant changes expected in those who were not overweight at baseline. primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03754920 - Prolonged Fasting With Meditation and Mild Physical Exercise N/A
Completed NCT05272332 - Gastric Ultrasound Prior to Extubation
Completed NCT04247464 - Short-term Fasting as an Enhancer of Chemotherapy: Pilot Clinical Study on Colorectal Carcinoma Patients N/A
Completed NCT01067001 - Minocycline HCl Extended Release Tablets 135 mg Oral Bioequivalence Study N/A
Completed NCT00757094 - Safety and Feasibility of Fasting While Receiving Chemotherapy N/A
Completed NCT01506713 - Bioequivalence Study of Clopidogrel Tablets 75 mg of Dr. Reddy's Under Fasting Conditions Phase 1
Completed NCT04514380 - Effect of Drinking Carbohydrate-containing Fluids on Gastric Residual Volume in Elderly Patients
Completed NCT05756868 - The Effect of Time-Restricted Feeding on Anthropometry, Biochemical Parameters, Diet Quality and Eating Behavior N/A
Completed NCT05134207 - The Effect of Oral Carbohydrate Solution on Anxiety and Comfort in Patients Undergoing Hip Arthroplasty N/A
Completed NCT05031598 - Long-term Fasting: Multi-system Adaptations in Humans N/A
Recruiting NCT04501393 - Recommended Clear Fluid Intake Volume at 2 Hours Prior to Esophagogastroduodenoscopy for Adult Patients N/A
Enrolling by invitation NCT04027478 - Can Fasting Decrease the Side Effects of Chemotherapy? N/A
Completed NCT05219136 - Improve the Comfort, Safety and Quality of Upper Endoscopy by a Modified Fasting Protocol N/A
Recruiting NCT04625608 - Effect of Premedicant Oral Paracetamol on Gastric Volume and pH Phase 4
Not yet recruiting NCT02562638 - Pre-Procedural Fasting in Cardiac Intervention N/A
Completed NCT01954836 - Short-Term Fasting During Chemotherapy in Patients With Gynecological Cancer- a Randomized Controlled Cross-over Trial N/A
Completed NCT01949987 - Does Oral Intake Decreases Postoperative Pain Score in Children N/A
Completed NCT01713647 - Bioequivalence Study of Amlodipine / Losartan/ Hydrochlorothiazide of PHARMALINE, Lebanon Under Fastion Conditions Phase 1
Completed NCT01831700 - Bioequivalence Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg Under Fasting Conditions Phase 1
Completed NCT01746719 - Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fasting Condition Phase 1